A live attenuated influenza vaccine (LAIV) was offered during the 2012-13 influenza season in Quebec, Canada, to children aged between 2 and 17 years with chronic medical conditions. Despite the offer, uptake of the vaccine was low. We assessed the perceptions and opinions about seasonal influenza vaccination and LAIV use among vaccine providers who participated in the 2012-13 campaign. More than 70% of them thought that LAIV was safe and effective and more than 90% considered that the vaccine was well-received by parents and healthcare professionals. According to respondents, the most frequent concerns of parents about LAIV were linked to vaccine efficacy. LAIV is well-accepted by vaccine providers involved in influenza vaccination clinics, but more information about the vaccine and the recommendations for its use are needed to increase vaccine uptake.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514394PMC
http://dx.doi.org/10.1080/21645515.2015.1009816DOI Listing

Publication Analysis

Top Keywords

vaccine providers
12
vaccine
10
live attenuated
8
attenuated influenza
8
influenza vaccine
8
quebec canada
8
influenza vaccination
8
influenza
5
laiv
5
acceptability live
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!